S
Shasqi
Oncology therapeutics that activate cancer drugs at the tumor via click chemistry, using its CAPAC (Click Activated Protodrugs Against Cancer) pre-targeting platform
About Shasqi
Shasqi is a clinical-stage biotechnology company using click chemistry to make cancer drugs more effective by activating them precisely at the tumor. Its proprietary CAPAC (Click Activated Protodrugs Against Cancer) platform combines a tumor-targeting binder with a systemically administered protodrug; when the two meet at the tumor, a click-chemistry reaction activates the drug locally, limiting exposure to healthy tissue. Shasqi was the first company to use click chemistry in humans.
Shasqi's lead asset is a CEACAM5-targeted binder paired with an MMAE protodrug, progressing toward the clinic, and the modular platform supports both chemotherapy and radioisotope payloads. First-in-human data published in Clinical Cancer Research (2025) describe SQ3370, an intratumorally injected biopolymer paired with a doxorubicin payload.
The company advances its platform through internal programs and research collaborations, including a research collaboration with Johnson & Johnson Enterprise Innovation applying CAPAC to new cancer therapies. Shasqi is headquartered in San Francisco, California.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- San Francisco, United States
- Employees
- 28
- Open positions
- 1
- Dealroom signal
- 69.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, YC W15, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2021 | $50M | $200M | Bill Rieflin | ↗ |
| GRANTOther financing | Apr 2021 | $2M | — | National Cancer Institute (NCI) | — |
Growth signals
Latest recorded traffic for Shasqi is 1.3K monthly website visits, up 8.3% over the last three months. Shasqi's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Y Combinator
US National Science Foundation
National Cancer Institute (NCI)
Series A1 investor entered at this stage
- BRBill Rieflin
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shasqi on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shasqi’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.